{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:58:08Z","timestamp":1785455888713,"version":"3.56.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-54391-6","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T05:46:46Z","timestamp":1779601606000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical features, outcomes, and prognostic factors of lymphocyte-depleted classical Hodgkin lymphoma: a population-based SEER analysis"],"prefix":"10.1038","volume":"16","author":[{"given":"Guoqing","family":"Lyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiankai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiesen","family":"Kou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,24]]},"reference":[{"key":"54391_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-020-0189-6","volume":"6","author":"JM Connors","year":"2020","unstructured":"Connors, J. M. et al. Hodgkin lymphoma. Nat. Rev. Dis. Primers. 6, 1\u201325 (2020).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"54391_CR2","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1002\/ajh.27470","volume":"99","author":"SM Ansell","year":"2024","unstructured":"Ansell, S. M. Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 99, 2367\u20132378 (2024).","journal-title":"Am. J. Hematol."},{"key":"54391_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-022-01281-9","volume":"15","author":"J Huang","year":"2022","unstructured":"Huang, J. et al. Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis. J. Hematol. Oncol. 15, 57 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"54391_CR4","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(20)32207-8","volume":"398","author":"P Brice","year":"2021","unstructured":"Brice, P., de Kerviler, E. & Friedberg, J. W. Classical Hodgkin lymphoma. Lancet 398, 1518\u20131527 (2021).","journal-title":"Lancet"},{"key":"54391_CR5","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.annonc.2025.02.004","volume":"36","author":"N Yamauchi","year":"2025","unstructured":"Yamauchi, N. & Maruyama, D. Progression-free survival: a true endpoint in first-line treatment for classic Hodgkin Lymphoma? Ann. Oncol. 36, 356\u2013358 (2025).","journal-title":"Ann. Oncol."},{"key":"54391_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-025-01257-1","volume":"15","author":"TJ Voorhees","year":"2025","unstructured":"Voorhees, T. J. et al. Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers. Blood Cancer J. 15, 45 (2025).","journal-title":"Blood Cancer J."},{"key":"54391_CR7","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1200\/JCO-24-01278","volume":"43","author":"P Torka","year":"2025","unstructured":"Torka, P. et al. Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma. J. Clin. Oncol. 43, 985\u2013993 (2025).","journal-title":"J. Clin. Oncol."},{"key":"54391_CR8","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1182\/bloodadvances.2024015048","volume":"9","author":"N Tabbara","year":"2025","unstructured":"Tabbara, N. et al. Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma. Blood Adv. 9, 1202\u20131209 (2025).","journal-title":"Blood Adv."},{"key":"54391_CR9","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1182\/blood.2024027782","volume":"145","author":"C Steidl","year":"2025","unstructured":"Steidl, C. The immunotherapy real estate of Hodgkin lymphoma. Blood 145, 1445\u20131447 (2025).","journal-title":"Blood"},{"key":"54391_CR10","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1200\/JCO.2011.36.4703","volume":"29","author":"B Klimm","year":"2011","unstructured":"Klimm, B. et al. Lymphocyte-depleted classical Hodgkin\u2019s lymphoma: a comprehensive analysis from the German Hodgkin study group. J. Clin. Oncol. 29, 3914\u20133920 (2011).","journal-title":"J. Clin. Oncol."},{"key":"54391_CR11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1053\/j.seminhematol.2024.05.001","volume":"61","author":"S Kosydar","year":"2024","unstructured":"Kosydar, S. & Ansell, S. M. The biology of classical Hodgkin lymphoma. Semin Hematol. 61, 212\u2013220 (2024).","journal-title":"Semin Hematol."},{"key":"54391_CR12","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","volume":"35","author":"MA Weniger","year":"2021","unstructured":"Weniger, M. A. & K\u00fcppers, R. Molecular biology of Hodgkin lymphoma. Leukemia 35, 968\u2013981 (2021).","journal-title":"Leukemia"},{"key":"54391_CR13","doi-asserted-by":"publisher","first-page":"101271","DOI":"10.1016\/j.blre.2025.101271","volume":"71","author":"MN Alibrahim","year":"2025","unstructured":"Alibrahim, M. N., Gloghini, A. & Carbone, A. Classic Hodgkin lymphoma: Pathobiological features that impact emerging therapies. Blood Rev. 71, 101271 (2025).","journal-title":"Blood Rev."},{"key":"54391_CR14","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2206125","volume":"387","author":"SM Ansell","year":"2022","unstructured":"Ansell, S. M. et al. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin\u2019s Lymphoma. N Engl. J. Med. 387, 310\u2013320 (2022).","journal-title":"N Engl. J. Med."},{"key":"54391_CR15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1182\/blood.2024024681","volume":"145","author":"HJ Lee","year":"2025","unstructured":"Lee, H. J. et al. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma. Blood 145, 290\u2013299 (2025).","journal-title":"Blood"},{"key":"54391_CR16","doi-asserted-by":"publisher","first-page":"982","DOI":"10.3324\/haematol.2023.283303","volume":"109","author":"HE Crosswell","year":"2023","unstructured":"Crosswell, H. E. et al. Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1. Haematologica 109, 982\u2013987 (2023).","journal-title":"Haematologica"},{"key":"54391_CR17","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","volume":"8","author":"DJ Straus","year":"2021","unstructured":"Straus, D. J. et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 8, e410\u2013e421 (2021).","journal-title":"Lancet Haematol."},{"key":"54391_CR18","doi-asserted-by":"publisher","first-page":"e2500288","DOI":"10.1200\/GO-25-00288","volume":"11","author":"JY Chan","year":"2025","unstructured":"Chan, J. Y. et al. Advanced Classical Hodgkin Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group. JCO Glob Oncol. 11, e2500288 (2025).","journal-title":"JCO Glob Oncol."},{"key":"54391_CR19","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.molmed.2024.10.004","volume":"31","author":"R K\u00fcppers","year":"2025","unstructured":"K\u00fcppers, R. Advances in Hodgkin lymphoma research. Trends Mol. Med. 31, 326\u2013343 (2025).","journal-title":"Trends Mol. Med."},{"key":"54391_CR20","doi-asserted-by":"publisher","first-page":"1067289","DOI":"10.3389\/fonc.2023.1067289","volume":"13","author":"F Ullah","year":"2023","unstructured":"Ullah, F., Dima, D., Omar, N., Ogbue, O. & Ahmed, S. Advances in the treatment of Hodgkin lymphoma: Current and future approaches. Front. Oncol. 13, 1067289 (2023).","journal-title":"Front. Oncol."},{"key":"54391_CR21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/bjh.18564","volume":"200","author":"H Shah","year":"2023","unstructured":"Shah, H., Jang, H., Kim, S. & Halwani, A. S. A comprehensive SEER registry analysis of elderly patients with classical Hodgkin lymphoma based on treatment era and race. Br. J. Haematol. 200, 579\u2013586 (2023).","journal-title":"Br. J. Haematol."},{"key":"54391_CR22","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.1200\/JCO.20.00264","volume":"38","author":"GM Dores","year":"2020","unstructured":"Dores, G. M., Curtis, R. E., Dalal, N. H., Linet, M. S. & Morton, L. M. Cause-Specific Mortality Following Initial Chemotherapy in a Population-Based Cohort of Patients With Classical Hodgkin Lymphoma, 2000\u20132016. J. Clin. Oncol. 38, 4149\u20134162 (2020).","journal-title":"J. Clin. Oncol."},{"key":"54391_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/j.seminhematol.2024.05.005","volume":"61","author":"M Kishida","year":"2024","unstructured":"Kishida, M., Fujisawa, M. & Steidl, C. Molecular biomarkers in classic Hodgkin lymphoma. Semin Hematol. 61, 221\u2013228 (2024).","journal-title":"Semin Hematol."},{"key":"54391_CR24","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1182\/blood.2025032560","volume":"147","author":"T Aoki","year":"2026","unstructured":"Aoki, T. & Kuruvilla, J. Targeted therapy in early-stage classical Hodgkin lymphoma. Blood 147, 1655\u20131657 (2026).","journal-title":"Blood"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54391-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54391-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54391-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:04:21Z","timestamp":1785452661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54391-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,24]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["54391"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-54391-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,24]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data used in this study were obtained from publicly available data in SEER databases and did not involve ethical approval or consent to participate.","order":2,"name":"Ethics","label":"Ethical a","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have consented to the publication of the manuscript.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23688"}}